ClinicalTrials.gg
CompletedNCT00704353Updated Feb 20, 2018Results posted

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

A Phase 3 interventional study of Ferric Carboxymaltose and Standard Medical Care (SMC) in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
735
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
6th of 54
735 · median 156
Started
2008
with 4 others
Phase 3
23 of 54
none open now
Registered
9th of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 6th largest by enrollment, is one of 5 that started in 2008, is one of 23 in phase 3, and was the 9th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent

03

Conditions studied

  • Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥18 years of age and able to give
  • Iron deficiency is the primary etiology of anemia
  • Screening Visit central laboratory indicative of anemia ≤12 g/dL
  • Screening Visit ferritin indicative of iron deficiency anemia ≤100 ng/mL or ≤300 when TSAT was ≤30%

Exclusion criteria

Exclusion Criteria:

  • Previous participation in a FCM trial
  • Known reaction to FCM
  • Requires dialysis for treatment of chronic kidney disease
  • Current anemia not attributed to iron deficiency
  • Received IV iron, RBC transfusion(s), or antibiotics 10 days prior and during the screening phase
  • Anticipated need for surgery requiring general anesthesia 30 days prior to screening or during the study period
  • of ALT greater than 1.5 times the
  • Received an drug within 30 days of screening
  • Pregnant or sexually-active females who are not able to use an effective form of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
735 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.

    Drug: Ferric Carboxymaltose

  • Active comparator
    Standard Medical Care

    Per product label

    Drug: Standard Medical Care (SMC)

Interventions

  • 15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.

  • DrugStandard Medical Care (SMC)

    Per product label

    Also known as: Ferrous Sulfate, Venofer, Ferrlecit, Infed, Dexferrum

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)

    Time frame: through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)

07

Results

Posted Nov 25, 2013

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Standard Medical Care
Started366369
Completed268255
Not completed98114

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAE's)
Time frame:
through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)
participantsFerric Carboxymaltose (FCM)Standard Medical Care
Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)59

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—5/366 (1.4%)0/366 (0%)
Standard Medical Care—9/369 (2.4%)0/369 (0%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventFerric Carboxymaltose (FCM)Standard Medical Care
PneumoniaInfections and infestations0/3662/369
Iron deficiency anemiaBlood and lymphatic system disorders1/3660/369
LeukocytosisBlood and lymphatic system disorders1/3660/369
Atrial fibrillationCardiac disorders1/3660/369
CardiomyopathyCardiac disorders1/3660/369
Gastrointestinal hemorrhageGastrointestinal disorders1/3660/369
Inappropriate device stimulation of tissueInjury, poisoning and procedural complications1/3660/369
DehydrationMetabolism and nutrition disorders1/3660/369
Respiratory distressRespiratory, thoracic and mediastinal disorders1/3660/369
Angina pectorisCardiac disorders0/3661/369

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM)Standard Medical CareTotal
<=18 years369
Between 18 and 65 years266265531
>=65 years9798195
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)Standard Medical CareTotal
Mean49.2 ± 19.9449.6 ± 19.8849.4 ± 19.91
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)Standard Medical CareTotal
Female322315637
Male445498
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)Standard Medical CareTotal
United States366369735
08

Study locations

1 site
  • Luitpold Pharmaceuticals
    Norristown, Pennsylvania 19403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2009 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2008
First posted
Jun 24, 2008
Start
Jun 2008
Primary completionActual
Jul 2009
CompletionActual
Mar 2011
Results first posted
Nov 25, 2013
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00704353
Responsible party
Sponsor
First posted
Jun 24, 2008
Start date
Jun 2008
Primary completion
Jul 2009
Completion
Mar 2011
Results posted
Nov 25, 2013
Last update
Feb 20, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion